Advertisement

Table of Contents

October 01, 1993; Volume 44,Issue 4

You have access
Structure and properties of omega-agatoxin IVB, a new antagonist of P-type calcium channels.
M E Adams, I M Mintz, M D Reily, V Thanabal and B P Bean

Molecular Pharmacology October 1993, 44 (4) 681-688;
You have access
Calcium entry via L-type calcium channels acts as a negative regulator of adenylyl cyclase activity and cyclic AMP levels in cardiac myocytes.
H J Yu, H Ma and R D Green

Molecular Pharmacology October 1993, 44 (4) 689-693;
You have access
Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
J Balzarini, A Karlsson and E De Clercq

Molecular Pharmacology October 1993, 44 (4) 694-701;
You have access
Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2',3'-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate.
S A Keilbaugh, G A Hobbs and M V Simpson

Molecular Pharmacology October 1993, 44 (4) 702-706;
You have access
Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.
Z Abdel-Razzak, P Loyer, A Fautrel, J C Gautier, L Corcos, B Turlin, P Beaune and A Guillouzo

Molecular Pharmacology October 1993, 44 (4) 707-715;
You have access
Drosophila nervous system muscarinic acetylcholine receptor: transient functional expression and localization by immunocytochemistry.
A D Blake, N M Anthony, H H Chen, J B Harrison, N M Nathanson and D B Sattelle

Molecular Pharmacology October 1993, 44 (4) 716-724;
You have access
5-hydroxytryptamine1C receptor density and mRNA levels in choroid plexus epithelial cells after treatment with mianserin and (-)-1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane.
E L Barker and E Sanders-Bush

Molecular Pharmacology October 1993, 44 (4) 725-730;
You have access
Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108-15 cells: increase in opioid agonist efficacy by decreased inactivation of G proteins.
D E Selley, C S Breivogel and S R Childers

Molecular Pharmacology October 1993, 44 (4) 731-741;
You have access
Biochemical and immunochemical comparison of saxiphilin and transferrin, two structurally related plasma proteins from Rana catesbeiana.
Y Li, L Llewellyn and E Moczydlowski

Molecular Pharmacology October 1993, 44 (4) 742-748;
You have access
Beta-[3H]funaltrexamine-labeled mu-opioid receptors: species variations in molecular mass and glycosylation by complex-type, N-linked oligosaccharides.
L Y Liu-Chen, C Chen and C A Phillips

Molecular Pharmacology October 1993, 44 (4) 749-756;
You have access
Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin.
R Bai, Z A Cichacz, C L Herald, G R Pettit and E Hamel

Molecular Pharmacology October 1993, 44 (4) 757-766;
You have access
Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
B Poddevin, J F Riou, F Lavelle and Y Pommier

Molecular Pharmacology October 1993, 44 (4) 767-774;
You have access
The phenobarbital-induced transcriptional activation of cytochrome P-450 genes is blocked by the glucocorticoid-progesterone antagonist RU486.
P M Shaw, M Adesnik, M C Weiss and L Corcos

Molecular Pharmacology October 1993, 44 (4) 775-783;
You have access
Coupling of expressed alpha 1B- and alpha 1D-adrenergic receptor to multiple signaling pathways is both G protein and cell type specific.
D M Perez, M B DeYoung and R M Graham

Molecular Pharmacology October 1993, 44 (4) 784-795;
You have access
Antisera against peptides derived from a purified mu-opioid binding protein recognize the protein as well as mu-opioid receptors in brain regions and a cell line.
T L Gioannini, Y H Yao, J M Hiller, L P Taylor and E J Simon

Molecular Pharmacology October 1993, 44 (4) 796-801;
You have access
Selective coupling of alpha 2-adrenergic receptor subtypes to cyclic AMP-dependent reporter gene expression in transiently transfected JEG-3 cells.
D J Pepperl and J W Regan

Molecular Pharmacology October 1993, 44 (4) 802-809;
You have access
Inositol-1,3,4,5-tetrakisphosphate induces calcium mobilization via the inositol-1,4,5-trisphosphate receptor in SH-SY5Y neuroblastoma cells.
R A Wilcox, R A Challiss, C Liu, B V Potter and S R Nahorski

Molecular Pharmacology October 1993, 44 (4) 810-817;
You have access
Indirect inhibition by bradykinin of cyclic AMP generation in isolated rat glomeruli and mesangial cells.
J L Bascands, C Pecher and J P Girolami

Molecular Pharmacology October 1993, 44 (4) 818-826;
You have access
BW373U86: a nonpeptidic delta-opioid agonist with novel receptor-G protein-mediated actions in rat brain membranes and neuroblastoma cells.
S R Childers, L M Fleming, D E Selley, R W McNutt and K J Chang

Molecular Pharmacology October 1993, 44 (4) 827-834;
You have access
A selective adenosine antagonist (8-cyclopentyl-1,3-dipropylxanthine) eliminates both neuromuscular depression and the action of exogenous adenosine by an effect on A1 receptors.
R S Redman and E M Silinsky

Molecular Pharmacology October 1993, 44 (4) 835-840;
You have access
Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues.
M Orbuch, J E Taylor, D H Coy, J E Mrozinski, S A Mantey, J F Battey, J P Moreau and R T Jensen

Molecular Pharmacology October 1993, 44 (4) 841-850;
You have access
Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors.
K Williams

Molecular Pharmacology October 1993, 44 (4) 851-859;
You have access
U-93631 causes rapid decay of gamma-aminobutyric acid-induced chloride currents in recombinant rat gamma-aminobutyric acid type A receptors.
G H Dillon, H K Im, B J Hamilton, D B Carter, R B Gammill, T M Judge and W B Im

Molecular Pharmacology October 1993, 44 (4) 860-865;
You have access
Potentiation of gamma-aminobutyric acid-induced chloride currents by various benzodiazepine site agonists with the alpha 1 gamma 2, beta 2 gamma 2 and alpha 1 beta 2 gamma 2 subtypes of cloned gamma-aminobutyric acid type A receptors.
H K Im, W B Im, B J Hamilton, D B Carter and P F Vonvoigtlander

Molecular Pharmacology October 1993, 44 (4) 866-870;
You have access
Ethanol inhibits a neuronal ATP-gated ion channel.
C Li, L Aguayo, R W Peoples and F F Weight

Molecular Pharmacology October 1993, 44 (4) 871-875;
You have access
Zinc selectively inhibits flux through benzodiazepine-insensitive gamma-aminobutyric acid chloride channels in cortical and cerebellar microsacs.
M F Davies, P A Maguire and G H Loew

Molecular Pharmacology October 1993, 44 (4) 876-881;
You have access
Role of threonine 342 in helix 7 of the 5-hydroxytryptamine type 1D receptor in ligand binding: an indirect mechanism for receptor selectivity.
A Smolyar and R Osman

Molecular Pharmacology October 1993, 44 (4) 882-885;
You have access
New activation model for the histamine H2 receptor, explaining the activity of the different classes of histamine H2 receptor agonists.
J C Eriks, H van der Goot and H Timmerman

Molecular Pharmacology October 1993, 44 (4) 886-894;
You have access
Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
S Yuasa, Y Sadakata, H Takashima, K Sekiya, N Inouye, M Ubasawa and M Baba

Molecular Pharmacology October 1993, 44 (4) 895-900;
You have access
Chemical properties of carbonic anhydrase IV, the membrane-bound enzyme.
T H Maren, G C Wynns and P J Wistrand

Molecular Pharmacology October 1993, 44 (4) 901-905;